# Electromed, Inc.: financial statements, quarterly

ELMD · NYSE · CIK 1488917 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/elmd.md) · [Financials](/companies/elmd/financials.md) · [Filings](/companies/elmd/filings.md) · [Insiders](/companies/elmd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/elmd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [12.3](/filings/0000897101-24-000563.md) | [13.7](/filings/0000897101-25-000089.md) | [13.9](/filings/0001437749-25-016450.md) | [14.8 d](/filings/0001437749-25-027761.md) | [14.7](/filings/0001437749-25-034445.md) | [16.3](/filings/0001437749-26-003635.md) | [15.7](/filings/0001437749-26-016429.md) | [17.4 d](/filings/0001437749-26-028914.md) | [16.9](/filings/0001437749-25-034445.md) | [18.9](/filings/0001437749-26-003635.md) | [18.6](/filings/0001437749-26-016429.md) | [19.4 d](/filings/0001437749-26-028914.md) |
| Cost of revenue | $m | [2.8](/filings/0000897101-24-000563.md) | [3.1](/filings/0000897101-25-000089.md) | [3.5](/filings/0001437749-25-016450.md) | [3.5 d](/filings/0001437749-25-027761.md) | [3.2](/filings/0001437749-25-034445.md) | [3.6](/filings/0001437749-26-003635.md) | [3.5](/filings/0001437749-26-016429.md) | [3.8 d](/filings/0001437749-26-028914.md) | [3.7](/filings/0001437749-25-034445.md) | [4.1](/filings/0001437749-26-003635.md) | [3.9](/filings/0001437749-26-016429.md) | [4.1 d](/filings/0001437749-26-028914.md) |
| Gross profit | $m | [9.5](/filings/0000897101-24-000563.md) | [10.5](/filings/0000897101-25-000089.md) | [10.4](/filings/0001437749-25-016450.md) | [11.3 d](/filings/0001437749-25-027761.md) | [11.5](/filings/0001437749-25-034445.md) | [12.6](/filings/0001437749-26-003635.md) | [12.2](/filings/0001437749-26-016429.md) | [13.6 d](/filings/0001437749-26-028914.md) | [13.2](/filings/0001437749-25-034445.md) | [14.8](/filings/0001437749-26-003635.md) | [14.6](/filings/0001437749-26-016429.md) | [15.3 d](/filings/0001437749-26-028914.md) |
| Research and development | $m | [0.2](/filings/0000897101-24-000563.md) | [0.1](/filings/0000897101-25-000089.md) | [0.2](/filings/0001437749-25-016450.md) | [0.2 d](/filings/0001437749-25-027761.md) | [0.2](/filings/0001437749-25-034445.md) | [0.3](/filings/0001437749-26-003635.md) | [0.3](/filings/0001437749-26-016429.md) | [0.3 d](/filings/0001437749-26-028914.md) | [0.2](/filings/0001437749-25-034445.md) | [0.4](/filings/0001437749-26-003635.md) | [0.4](/filings/0001437749-26-016429.md) | [0.3 d](/filings/0001437749-26-028914.md) |
| Selling, general and administrative | $m | [9.2](/filings/0000897101-24-000563.md) | [8.2](/filings/0000897101-25-000089.md) | [8.4](/filings/0001437749-25-016450.md) | [8.8 d](/filings/0001437749-25-027761.md) | [9.4](/filings/0001437749-25-034445.md) | [9.8](/filings/0001437749-26-003635.md) | [9.8](/filings/0001437749-26-016429.md) | [10.3 d](/filings/0001437749-26-028914.md) | [10.3](/filings/0001437749-25-034445.md) | [10.8](/filings/0001437749-26-003635.md) | [10.5](/filings/0001437749-26-016429.md) | [11.1 d](/filings/0001437749-26-028914.md) |
| Operating income | $m | [0.1](/filings/0000897101-24-000563.md) | [2.3](/filings/0000897101-25-000089.md) | [1.8](/filings/0001437749-25-016450.md) | [2.3 d](/filings/0001437749-25-027761.md) | [1.9](/filings/0001437749-25-034445.md) | [2.5](/filings/0001437749-26-003635.md) | [2.1](/filings/0001437749-26-016429.md) | [3.0 d](/filings/0001437749-26-028914.md) | [2.7](/filings/0001437749-25-034445.md) | [3.6](/filings/0001437749-26-003635.md) | [3.8](/filings/0001437749-26-016429.md) | [3.8 d](/filings/0001437749-26-028914.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.1](/filings/0000897101-24-000563.md) | [0.7](/filings/0000897101-25-000089.md) | [0.5](/filings/0001437749-25-016450.md) | [0.7 d](/filings/0001437749-25-027761.md) | [0.7](/filings/0001437749-25-034445.md) | [0.7](/filings/0001437749-26-003635.md) | [0.4](/filings/0001437749-26-016429.md) | [1.0 d](/filings/0001437749-26-028914.md) | [0.7](/filings/0001437749-25-034445.md) | [1.0](/filings/0001437749-26-003635.md) | [0.9](/filings/0001437749-26-016429.md) | [0.6 d](/filings/0001437749-26-028914.md) |
| Net income | $m | [0.2](/filings/0001437749-25-016450.md) | [1.7](/filings/0001437749-25-016450.md) | [1.5](/filings/0001437749-25-016450.md) | [1.8 d](/filings/0001437749-25-027761.md) | [1.5](/filings/0001437749-26-016429.md) | [2.0](/filings/0001437749-26-016429.md) | [1.9](/filings/0001437749-26-016429.md) | [2.2 d](/filings/0001437749-26-028914.md) | [2.1](/filings/0001437749-26-016429.md) | [2.8](/filings/0001437749-26-016429.md) | [3.0](/filings/0001437749-26-016429.md) | [3.4 d](/filings/0001437749-26-028914.md) |
| Diluted EPS | $ per share | [0.02](/filings/0000897101-24-000563.md) | [0.19](/filings/0000897101-25-000089.md) | [0.17](/filings/0001437749-25-016450.md) | not reported | [0.16](/filings/0001437749-25-034445.md) | [0.22](/filings/0001437749-26-003635.md) | [0.21](/filings/0001437749-26-016429.md) | not reported | [0.25](/filings/0001437749-25-034445.md) | [0.32](/filings/0001437749-26-003635.md) | [0.35](/filings/0001437749-26-016429.md) | not reported |
| Basic EPS | $ per share | [0.02](/filings/0000897101-24-000563.md) | [0.20](/filings/0000897101-25-000089.md) | [0.17](/filings/0001437749-25-016450.md) | not reported | [0.17](/filings/0001437749-25-034445.md) | [0.23](/filings/0001437749-26-003635.md) | [0.22](/filings/0001437749-26-016429.md) | not reported | [0.26](/filings/0001437749-25-034445.md) | [0.33](/filings/0001437749-26-003635.md) | [0.37](/filings/0001437749-26-016429.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [7.0](/filings/0000897101-23-000477.md) | [10.4](/filings/0000897101-24-000070.md) | [11.7](/filings/0000897101-24-000163.md) | [16.1](/filings/0001437749-25-027761.md) | [13.9](/filings/0000897101-24-000563.md) | [16.2](/filings/0000897101-25-000089.md) | [15.2](/filings/0001437749-25-016450.md) | [15.3](/filings/0001437749-26-028914.md) | [14.1](/filings/0001437749-25-034445.md) | [13.8](/filings/0001437749-26-003635.md) | [17.0](/filings/0001437749-26-016429.md) | [20.5](/filings/0001437749-26-028914.md) |
| Current assets | $m | [36.2](/filings/0000897101-23-000477.md) | [39.3](/filings/0000897101-24-000070.md) | [41.3](/filings/0000897101-24-000163.md) | [44.2](/filings/0001437749-25-027761.md) | [41.0](/filings/0000897101-24-000563.md) | [44.2](/filings/0000897101-25-000089.md) | [44.2](/filings/0001437749-25-016450.md) | [45.1](/filings/0001437749-26-028914.md) | [44.6](/filings/0001437749-25-034445.md) | [45.6](/filings/0001437749-26-003635.md) | [50.2](/filings/0001437749-26-016429.md) | [57.4](/filings/0001437749-26-028914.md) |
| Total assets | $m | [44.1](/filings/0000897101-23-000477.md) | [47.0](/filings/0000897101-24-000070.md) | [48.9](/filings/0000897101-24-000163.md) | [52.2](/filings/0001437749-25-027761.md) | [48.9](/filings/0000897101-24-000563.md) | [52.3](/filings/0000897101-25-000089.md) | [52.5](/filings/0001437749-25-016450.md) | [53.8](/filings/0001437749-26-028914.md) | [53.6](/filings/0001437749-25-034445.md) | [54.9](/filings/0001437749-26-003635.md) | [59.5](/filings/0001437749-26-016429.md) | [66.3](/filings/0001437749-26-028914.md) |
| Current liabilities | $m | [5.8](/filings/0000897101-23-000477.md) | [6.6](/filings/0000897101-24-000070.md) | [6.3](/filings/0000897101-24-000163.md) | [7.7](/filings/0001437749-25-027761.md) | [7.4](/filings/0000897101-24-000563.md) | [8.7](/filings/0000897101-25-000089.md) | [8.5](/filings/0001437749-25-016450.md) | [10.5](/filings/0001437749-26-028914.md) | [8.8](/filings/0001437749-25-034445.md) | [9.4](/filings/0001437749-26-003635.md) | [10.2](/filings/0001437749-26-016429.md) | [12.2](/filings/0001437749-26-028914.md) |
| Total liabilities | $m | [5.8](/filings/0000897101-23-000477.md) | [6.6](/filings/0000897101-24-000070.md) | [6.4](/filings/0000897101-24-000163.md) | [7.7](/filings/0001437749-25-027761.md) | [7.4](/filings/0000897101-24-000563.md) | [8.7](/filings/0000897101-25-000089.md) | [8.5](/filings/0001437749-25-016450.md) | [10.6](/filings/0001437749-26-028914.md) | [8.9](/filings/0001437749-25-034445.md) | [9.5](/filings/0001437749-26-003635.md) | [10.3](/filings/0001437749-26-016429.md) | [12.3](/filings/0001437749-26-028914.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [38.2](/filings/0001437749-25-016450.md) | [40.3](/filings/0001437749-25-016450.md) | [42.5](/filings/0001437749-25-016450.md) | [44.5](/filings/0001437749-26-028914.md) | [41.5](/filings/0001437749-26-016429.md) | [43.6](/filings/0001437749-26-016429.md) | [43.9](/filings/0001437749-26-016429.md) | [43.2](/filings/0001437749-26-028914.md) | [44.7](/filings/0001437749-26-016429.md) | [45.4](/filings/0001437749-26-016429.md) | [49.2](/filings/0001437749-26-016429.md) | [54.0](/filings/0001437749-26-028914.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(244)](/filings/0000897101-24-000563.md) | [3,471 d](/filings/0000897101-25-000089.md) | [1,351 d](/filings/0001437749-25-016450.md) | [4,489 d](/filings/0001437749-25-027761.md) | [2,309](/filings/0001437749-25-034445.md) | [3,151 d](/filings/0001437749-26-003635.md) | [2,074 d](/filings/0001437749-26-016429.md) | [3,859 d](/filings/0001437749-26-028914.md) | [169](/filings/0001437749-25-034445.md) | [3,026 d](/filings/0001437749-26-003635.md) | [3,476 d](/filings/0001437749-26-016429.md) | [2,994 d](/filings/0001437749-26-028914.md) |
| Capital expenditure | $k | [109](/filings/0000897101-24-000563.md) | [71.0 d](/filings/0000897101-25-000089.md) | [85.0 d](/filings/0001437749-25-016450.md) | [22.0 d](/filings/0001437749-25-027761.md) | [37.0](/filings/0001437749-25-034445.md) | [233 d](/filings/0001437749-26-003635.md) | [(153) d](/filings/0001437749-26-016429.md) | [145 d](/filings/0001437749-26-028914.md) | [252](/filings/0001437749-25-034445.md) | [634 d](/filings/0001437749-26-003635.md) | [147 d](/filings/0001437749-26-016429.md) | [219 d](/filings/0001437749-26-028914.md) |
| Share repurchases | $k | not reported | not reported | not reported | [275 d](/filings/0001437749-25-027761.md) | [4,536](/filings/0001437749-25-034445.md) | [0.0 d](/filings/0001437749-26-003635.md) | [1,795 d](/filings/0001437749-26-016429.md) | [3,669 d](/filings/0001437749-26-028914.md) | [1,003](/filings/0001437749-25-034445.md) | [2,763 d](/filings/0001437749-26-003635.md) | [152 d](/filings/0001437749-26-016429.md) | [0.0 d](/filings/0001437749-26-028914.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [8,689](/filings/0000897101-23-000477.md) | [8,684](/filings/0000897101-24-000070.md) | [8,710](/filings/0000897101-24-000163.md) | [8,783](/filings/0000897101-24-000563.md) | [8,800](/filings/0000897101-25-000089.md) | [8,893](/filings/0001437749-25-016450.md) | [8,981](/filings/0001437749-25-034445.md) | [8,953](/filings/0001437749-26-003635.md) | [8,968](/filings/0001437749-26-016429.md) | [8,682](/filings/0001437749-25-034445.md) | [8,689](/filings/0001437749-26-003635.md) | [8,648](/filings/0001437749-26-016429.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 8,366,163 at 2026-08-19, from the cover of the [10-K filed 2026-08-25](/filings/0001437749-26-028914.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.